Acceleron Pharma, Inc.
A biopharmaceutical company developing novel therapeutics to modulate the growth of tissues including bone and muscle. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of tissues such as blood, bone, muscle and blood vessels. Based on this expertise, Acceleron has built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases, cancer and neuromuscular diseases. The company went public in September 2013 (NASDAQ: XLRN).